Stone X Group Inc. Alzamend Neuro, Inc. Transaction History

Stone X Group Inc.

  • $2.29 Trillion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Aug 13, 2025
BUY
$0.53 - $222.0 $5,832 - $2.44 Million
11,005 New
11,005 $6.22 Million

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $213M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email